Ruthenium Polypyridine Complexes Research Articles

Electrochemistry of different ruthenium polypyridine complexes

In search for antitumor metal-based drugs that would mitigate the severe side-effects of cisplatin, Ru(II) complexes are gaining increasing recent interest. Their cytotoxic effect is widely known, however mechanism of action, solution behavior, redox reactions within biological system are still focus of the new studies. Various experiments and approach techniques are used to better understand ruthenium chemistry. In this order their biological activity and the availability of reduction potential in the biological medium, it is necessary to know their electrochemical redox behavior and properties. In this work, we report the electrochemical activity on synthesized and characterized (1H- and 13C NMR, FT-IR, MS) half-sandwich organometallic Ru(II) complexes of the general formula [Ru(η6-arene)(XY)Cl](PF6) where arene = benzene, toluene or p-cymene and XY = bidentates: dipyrido[3,2-a:2′,3′-c]phenazine (dppz derivatives) or 2-(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline (aip), which are bound to Ru(II) via two phenanthroline-N atoms in a characteristic “piano-stool” configuration of Ru(II)-arene complexes – as confirmed by vibrational and NMR spectra. It is shown that selected complexes can be divided in four groups, based on their electrochemical behavior. These behaviors are correlated with their structure and nature of ligands.

Cover Feature: Unlocking the Fluorine‐Free Buoy Effect: Surface‐Enriched Ruthenium Polypyridine Complexes in Ionic Liquids (ChemistryOpen 7/2024)

Cover Feature: Unlocking the Fluorine‐Free Buoy Effect: Surface‐Enriched Ruthenium Polypyridine Complexes in Ionic Liquids (ChemistryOpen 7/2024)

Unlocking the Fluorine-Free Buoy Effect: Surface-Enriched Ruthenium Polypyridine Complexes in Ionic Liquids.

Controlling the local concentration of metal complexes at the surface of ionic liquids (ILs) is a highly sought-after objective due to its pivotal implications in supported ionic liquid phase (SILP) catalysis. Equally important is to avoid per- and polyfluorinated substances due to environmental concerns. Herein, we investigate the surface enrichment of Ru polypyridyl complexes with fluorine-free alkylic side groups of varying lengths and shapes, using the hydrophilic IL [C2C1Im][OAc] as solvent. Additional charged carboxylate groups are included into the polypyridyl ligands to increase the solubility of the complex in the IL. When the ligand system is functionalized with long and hydrophobic alkyl side chains, the complex predominantly localizes at the IL/vacuum interface, as deduced from angle-resolved X-ray photoelectron spectroscopy. Conversely, in the presence of short or more bulky substituents, no surface enrichment is observed. This buoy-like behaviour with fluorine-free side groups is explored for 0.05 %mol to 1 %mol solutions. Intriguingly, surface saturation occurs at approximately 0.5 %mol, which is beneficial to the efficient operation of catalytic systems featuring high surface areas, such as SILP catalysts.

Modulation of the Excited States of Ruthenium(II)-perylene Dyad to Access Near-IR Luminescence, Long-Lived Perylene Triplet State and Singlet Oxygen Photosensitization.

Herein, we present a novel ruthenium(II)-perylene dyad (RuPDI-Py) that combines the photophysical properties of pyrrolidine-substituted perylene diimide (PDI-Py) and the ruthenium(II) polypyridine complex [Ru(phen)3]2+. A comprehensive study of excited-state dynamics was carried out using time-resolved and steady-state methods in a dimethyl sulfoxide solution. The RuPDI-Py dyad demonstrated excitation wavelength-dependent photophysical behavior. Upon photoexcitation above 600 nm, the dyad exclusively exhibits the near-infrared (NIR) fluorescence of the 1PDI-Py state at 785 nm (τfl = 1.50 ns). In contrast, upon photoexcitation between 350 and 450 nm, the dyad also exhibits a photoinduced electron transfer from the {[Ru(phen)3]2+} moiety to PDI-Py, generating the charge-separated intermediate state {Ru(III)-(PDI-Py)•-} (4 μs). This state subsequently decays to the long-lived triplet excited state 3PDI-Py (36 μs), which is able to sensitize singlet oxygen (1O2). Overall, tuning 1O2 photoactivation or NIR fluorescence makes RuPDI-Py a promising candidate for using absorbed light energy to perform the desired functions in theranostic applications.

SÍNTESE, FOTORREATIVIDADE E INTERAÇÃO COM DNA DE UM NOVO COMPLEXO DE RUTÊNIO PROTÓTIPO PARA O DESENVOLVIMENTO DE AGENTES FOTOQUIMIOTERAPÊUTICOS

SYNTHESIS, PHOTOREACTIVITY AND INTERACTION WITH DNA OF A NEW PROTOTYPE RUTHENIUM COMPLEX FOR THE DEVELOPMENT OF PHOTOCHEMOTHERAPEUTIC AGENTS. A new ruthenium polypyridine complex, cis-[Ru(bpy)2(1- meimN)(4-pyCHO)](PF6)2 (WP1), where 1-meimN and pyCHO are the ligands 1-methylimidazole and 4-pyridinecarboxaldehyde, respectively, was prepared as a prototype for use in phototherapeutic process. This compound was characterized by electronic absorption in UV-Visible, FTIR, 1H and 13C NMR, cyclic voltammetry, besides DFT that supported its molecular structure. The compound WP1 was photoreactive, where blue or green light promoted the release of 4-pyCHO ligand. Additionally, this compound was able to interact with DNA, mainly through electrostatic interactions showing photoinduced nuclease activity. There is also photoproduction of superoxide ions using blue or green light suggesting a route for DNA damage. These promising results opened new opportunities for the potential use of this system and analogues as phototherapeutic agents, which is an ongoing study in our lab.

Rational design of a red-light absorbing ruthenium polypyridine complex as a photosensitizer for photodynamic therapy.

Herein, the computer-guided design, chemical synthesis, and biological evaluation of a RuC polypyridine complex, that could eradicate cancerous cells upon excitation with red light at 630 nm, is reported.

8-Hydroxyquinoline ruthenium(II) complexes induce ferroptosis in HeLa cells by down-regulating GPX4 and ferritin

Ruthenium complexes are one of the most promising anticancer drugs triggered extensive research. Here, the synthesis and characterization of two ruthenium(II) polypyridine complexes containing 8-hydroxylquinoline as ligand, [Ru(dip)2(8HQ)]PF6 (Ru1), [Ru(dpq)2(8HQ)]PF6 (Ru2) (8HQ = 8-hydroxylquinoline; dip = 4,7-diphenyl-1,10-phenanthroline; dpq = pyrazino[2,3-f][1,10]phenanthroline) were reported. On the basis of cytotoxicity tests, Ru1 (IC50 = 1.98 ± 0.02 μM) and Ru2 (IC50 = 10.02 ± 0.19 μM) both showed good anticancer activity in a panel of cell lines, especially in HeLa cells. Researches on mechanism indicated that Ru1 and Ru2 acted on mitochondria and nuclei and induced reactive oxygen species (ROS) accumulation, while the morphology of nuclei and cell cycle had no significant change. Western blot assay further proved that GPX4 and Ferritin were down-regulated, which eventually triggered ferroptosis in HeLa cells. In addition, the toxicity test of zebrafish embryos showed that the concentrations of Ru1 and Ru2 below 120 μM and 60 μM were safe and did not have obvious effect on the normal development of zebrafish embryos.

Ruthenium polypyridine complexes containing prenyl groups as antibacterial agents against Staphylococcus aureus through a membrane-disruption mechanism.

Four new ruthenium polypyridyl complexes with prenyl groups, [Ru(bpy)2 (MHIP)](PF6 )2 (Ru(II)-1), [Ru(dtb)2 (MHIP)](PF6 )2 (Ru(II)-2), [Ru(dmb)2 (MHIP)](PF6 )2 (Ru(II)-3), and [Ru(dmob)2 (MHIP)](PF6 )2 (Ru(II)-4) (bpy = 2,2'-bipyridine, dtb = 4,4'-di-tert-butyl-2,2'-bipyridine, dmb = 4,4'-dimethyl-2,2'-bipyridine, dmob = 4,4'-dimethoxy-2,2'-bipyridine, and MHIP = 2-(2,6-dimethylhepta-1,5-dien-1-yl)-1H-imidazo[4,f][1,10]phenanthroline), were synthesized and characterized. Their antibacterial activities against Staphylococcus aureus were assessed, and the minimum inhibition concentration (MIC) value of Ru(II)-2 against S. aureus was only 0.5 µg/mL, showing the best antibacterial activity among them. S. aureus could be quickly killed by Ru(II)-2 in 30 min and Ru(II)-2 displayed an obvious inhibitive effect on the formation of a biofilm, which was essential to avoid the development of drug-resistance. Meanwhile, Ru(II)-2 exhibited a stable MIC value against antibiotic-resistant bacteria. The antibacterial mechanism of Ru(II)-2 was probably related to depolarization of the cell membrane, and a change of permeability was associated with the formation of reactive oxygen species, leading to leakage of nucleic acid and bacterial death. Furthermore, Ru(II)-2 hardly showed toxicity to mammalian cells and the Galleria mellonella worm. Finally, murine infection studies also illustrated that Ru(II)-2 was highly effective against S. aureus in vivo.

Specific discrimination and efficient elimination of gram-positive bacteria by an aggregation-induced emission-active ruthenium (II) photosensitizer.

The infections caused by Gram-positive bacteria (G+) have seriously endangered public heath due to their high morbidity and mortality. Therefore, it is urgent to develop a multifunctional system for selective recognition, imaging and efficient eradication of G+. Aggregation-induced emission materials have shown great promise for microbial detection and antimicrobial therapy. In this paper, a multifunctional ruthenium (II) polypyridine complex Ru2 with aggregation-induced emission (AIE) characteristic, was developed and used for selective discrimination and efficient extermination of G+ from other bacteria with unique selectivity. The selective G+ recognition benefited from the interaction between lipoteichoic acids (LTA) and Ru2. Accumulation of Ru2 on the G+ membrane turned on its AIE luminescence and allowed specific G+ staining. Meanwhile, Ru2 under light irradiation also possessed robust antibacterial activity for G+in vitro and in vivo antibacterial experiments. To the best of our knowledge, Ru2 is the first Ru-based AIEgen photosensitizer for simultaneous dual applications of G+ detection and treatment, and inspires the development of promising antibacterial agents in the future.

A Photoactivated Ru (II) Polypyridine Complex Induced Oncotic Necrosis of A549 Cells by Activating Oxidative Phosphorylation and Inhibiting DNA Synthesis as Revealed by Quantitative Proteomics.

The ruthenium polypyridine complex [Ru(dppa)2(pytp)] (PF6)2 (termed as ZQX-1), where dppa = 4,7-diphenyl-1,10-phenanthroline and pytp = 4'-pyrene-2,2':6',2''-terpyridine, has been shown a high and selective cytotoxicity to hypoxic and cisplatin-resistant cancer cells either under irradiation with blue light or upon two-photon excitation. The IC50 values of ZQX-1 towards A549 cancer cells and HEK293 health cells are 0.16 ± 0.09 µM and >100 µM under irradiation at 420 nm, respectively. However, the mechanism of action of ZQX-1 remains unclear. In this work, using the quantitative proteomics method we identified 84 differentially expressed proteins (DEPs) with |fold-change| ≥ 1.2 in A549 cancer cells exposed to ZQX-1 under irradiation at 420 nm. Bioinformatics analysis of the DEPs revealed that photoactivated ZQX-1 generated reactive oxygen species (ROS) to activate oxidative phosphorylation signaling to overproduce ATP; it also released ROS and pyrene derivative to damage DNA and arrest A549 cells at S-phase, which synergistically led to oncotic necrosis and apoptosis of A549 cells to deplete excess ATP, evidenced by the elevated level of PRAP1 and cleaved capase-3. Moreover, the DNA damage inhibited the expression of DNA repair-related proteins, such as RBX1 and GPS1, enhancing photocytotoxicity of ZQX-1, which was reflected in the inhibition of integrin signaling and disruption of ribosome assembly. Importantly, the photoactivated ZQX-1 was shown to activate hypoxia-inducible factor 1A (HIF1A) survival signaling, implying that combining use of ZQX-1 with HIF1A signaling inhibitors may further promote the photocytotoxicity of the prodrug.

PH dependent spectrophotometric study, cytotoxicity and antimicrobial activity of mononuclear ruthenium(II) polypyridine complexes

pH dependent spectrophotometric study, cytotoxicity and antimicrobial activity of mononuclear ruthenium(II) polypyridine complexes

Synthesis and biological evaluation of ruthenium complexes bearing the 1,2,4-triazole group as potential membrane-targeting antibacterial agents towards Staphylococcus aureus.

Bacterial infection is one of the most serious public health problems, being harmful to human health and expensive. Nowadays, the misuse and overuse of antibiotics have led to the emergence of drug resistance. Therefore, it is an urgent need to develop new antimicrobial agents to address the current situation. In this study, four 1,2,4-triazole ruthenium polypyridine complexes [Ru(bpy)2(TPIP)](PF6)2 (Ru1), [Ru(dmb)2(TPIP)](PF6)2 (Ru2), [Ru(dtb)2(TPIP)](PF6)2 (Ru3) and [Ru(dmob)2(TPIP)](PF6)2 (Ru4) (bpy = 2,2'-bipyridine, dmb = 4,4'-dimethyl-2,2'-bipyridine, dtb = 4,4'-di-tert-butyl-2,2'-bipyridine, dmob = 4,4'-dimethoxy-2,2'-bipyridine and TPIP = 2-(4-(1H-1,2,4-triazol-1-yl)phenyl)-1H-imidazo[4,5-f][1,10]phenanthroline) were synthesized and evaluated for antibacterial activity. Results showed that the minimum inhibitory concentration (MIC) value of Ru3 against Staphylococcus aureus (S. aureus) was only 0.78 μg mL-1, showing the best antimicrobial activity in vitro. Besides, Ru3 showed low hemolytic activity and good biocompatibility. Due to its ability to damage the cell membrane of Staphylococcus bacteria, Ru3 was able to kill bacteria in a short time. Importantly, by inhibiting bacterial toxins and the formation of biofilm, Ru3 was not susceptible to the development of drug resistance. Moreover, Ru3 revealed excellent therapeutic effects in vivo and showed no irritation to the skin of mice. In conclusion, the four obtained 1,2,4-triazole ruthenium polypyridine complexes show strong antibacterial activity and satisfactory biocompatibility with excellent potential for antibacterial treatment, and provide a new solution for the current antibacterial crisis.

Multi-target antibacterial mechanism of ruthenium polypyridine complexes with anthraquinone groups against Staphylococcus aureus.

Three new Ru(ii) complexes, [Ru(dtb)2PPAD](PF6)2 (Ru-1), [Ru(dmob)2PPAD](PF6)2 (Ru-2) and [Ru(bpy)2PPAD](PF6)2 (Ru-3) (dtb = 4,4'-di-tert-butyl-2,2'-bipyridine, dmob = 4,4'-dimethyl-2,2'-bipyridine, bpy = 2,2'-bipyridine and PPAD = 2-(pyridine-3-yl)-1H-imidazo[4,5f][1.10]phenanthracene-9,10-dione), were synthesized and characterized by 1H NMR and 13C NMR spectroscopy, HRMS and HPLC. Among them, Ru-1 showed excellent antimicrobial activity against Gram-positive bacteria Staphylococcus aureus (minimum inhibitory concentration (MIC) = 1 μg mL-1) and low hemolytic and cytotoxic activity. In addition, Ru-1 showed obviously rapid bactericidal activity, low resistance rate, bacterial biofilm destroying activity and high biosafety in vivo. Moreover, skin infection models and a mouse model of sepsis indicated that the anti-infective efficacy of Ru-1 was comparable to that of vancomycin. Mechanism exploration results showed that the antibacterial behavior is probably related with targeting of the bacterial cell membrane and inhibiting topoisomerase I.

Tuning the Photocatalytic Performance of Ruthenium(II) Polypyridine Complexes Via Ligand Modification for Visible-Light-Induced Phosphorylation of Tertiary Aliphatic Amines.

Tuning the redox potential of commonly available photocatalyst to improve the catalytic performance or expand its scope for challenging synthetic conversions is an ongoing demand in synthetic chemistry. Herein, the excited state properties and redox potential of commercially available [Ru(bpy)3 ]2+ photocatalyst were tuned by modifying the structure of the bipyridine ligands with electron-donating/withdrawing units. The visible-light-mediated photoredox phosphorylation of tertiary aliphatic amines was demonstrated under mild conditions. A series of cross-dehydrogenative coupling reactions were performed employing the RuII complexes as photocatalyst giving the corresponding α-aminophosphinoxides and α-aminophosphonates via carbon-phosphorus (C-P) bond formation.

Ruthenium polypyridine complexes with triphenylamine groups as antibacterial agents against Staphylococcus aureus with membrane-disruptive mechanism.

Due to the emergence and wide spread of methicillin-resistant Staphylococcus aureus, the treatment of this kind of infection becomes more and more difficult. To solve the problem of drug resistance, it is urgent to develop new antibiotics to avoid the most serious situation of no drug available. Three new Ru complexes [Ru (dmob)2PMA] (PF6)2 (Ru-1) [Ru (bpy)2PMA] (PF6)2 (Ru-2) and [Ru (dmb)2PMA] (PF6)2 (Ru-3) (dmob = 4,4′-dimethoxy-2,2′-bipyridine, bpy = 2,2′-bipyridine, dmb = 4,4′-dimethyl-2,2′-bipyridine and PMA = N-(4-(1H-imidazo [4,5-f] [1,10] phenanthrolin-2-yl) -4-methyl-N-(p-tolyl) aniline) were synthesized and characterized by 1H NMR, 13C NMR and HRMS. The detailed molecular structure of Ru-3 was determined by single crystal X-ray diffraction. Their antibacterial activities against Staphylococcus aureus (Staphylococcus aureus) were obvious and Ru-3 showed the best antibacterial effect with the minimum inhibitory concentration value of 4 μg ml−1. Therefore, further study on its biological activity showed that Ru-3 can effectively inhibit the formation of biofilm and destroy cell membrane. In vitro hemolysis test showed that Ru-3 has almost negligible cytotoxicity to mammalian red blood cells. In the toxicity test of wax moth insect model, Ru-3 exhibited low toxicity in vivo. These results, combined with histopathological studies, strongly suggest that Ru-3 was almost non-toxic. In addition, the synergistic effect of Ru-3 with common antibiotics such as ampicillin, chloramphenicol, tetracycline, kanamycin and gentamicin on Staphylococcus aureus was detected by chessboard method. Finally, in vivo results revealed that Ru-3 could obviously promote the wound healing of Staphylococcus aureus infected mice.

Synthesis and antibacterial against Staphylococcus aureus of new ruthenium (II) polypyridine complexes containing pyrene groups

AbstractAs the treatment of Staphylococcus aureus infection becomes more and more difficult, it is particularly important to develop new antibacterial agents against S. aureus infection. Herein, three ruthenium (II) complexes containing pyrene groups, [Ru (bpy)2(PYIP)](PF6)2 (Ru‐1), [Ru (dtbpy)2(PYIP)](PF6)2 (Ru‐2), and [Ru (ttbpy)2(PYIP)](PF6)2 (Ru‐3) (PYIP = 2‐(pyren‐1‐yl‐1H‐imidazo[4,5‐f][1,10]phenanthroline, bpy = 2,2′‐bipyridine, dtbpy = 4,4′‐dimethyl‐2,2′‐bipyridine and ttbpy = 4,4′‐di‐tert‐butyl‐2,2′‐bipyridine) were designed and synthesized. The antibacterial activities of them against S. aureus were evaluated by determining the minimum inhibitory concentration and minimum bactericidal concentration. The results showed that three ruthenium complexes had excellent antibacterial activities against S. aureus. Among them, Ru‐2 exhibited the best bacteriostatic concentration and bactericidal activities, which was selected for the further antibacterial mechanism exploring. Ru‐2 can obviously inhibit the growth of bacterial biofilm, and the drug resistance results showed that Ru‐2 can effectively prevent the development of bacterial resistance. Moreover, the in vivo antibacterial activity of Ru‐2 was evaluated by establishing mouse infection model with the results that Ru‐2 could effectively inhibit the growth of bacteria and make mouse wounds heal faster.

Theranostic Ruthenium Polypyridine Nanoparticles for Targeted Chimera Delivery into Ovarian Cancer Cells

Efficient in vivo delivery of small interfering RNAs (siRNAs) to target cells is challenging in clinical applications. Ruthenium (II) polypyridyl complexes have been discovered as imaging theranostic and anticancer agents due to their photophysical and biological properties. However, the clinical implementation of ruthenium complexes is limited by cancer cell selectivity. This study presents a novel siRNA delivery nanoplatform by ruthenium polypyridine complex nanoparticles (RPNs). The EGFR RNA aptamer and Notch3 siRNA chimera-loaded RPNs showed superior RNAi effects against Notch3 gene compared to Lipofectamine. Also, RPN-chimera complexes exhibited significant in vivo antitumor effects against ovarian cancer, which exhibited much potential in future cancer imaging guided gene therapy.

Synthesis of ruthenium polypyridine complexes with benzyloxyl groups and their antibacterial activities against Staphylococcus aureus

Four new ruthenium polypyridyl complexes, [Ru(bpy)2(BPIP)](PF6)2 (Ru(II)-1), [Ru(dtb)2(BPIP)](PF6)2 (Ru(II)-2), [Ru(dmb)2(BPIP)](PF6)2 (Ru(II)-3) and [Ru(dmob)2(BPIP)](PF6)2 (Ru(II)-4) (bpy = 2,2′-bipyridine, dtb = 4,4′-di-tert-butyl-2,2′-bipyridine, dmb = 4,4′-dimethyl-2,2′-bipyridine, dmob = 4,4′-dimethoxy-2,2′-bipyridine and BPIP = 2-(3,5-bis(benzyloxyl)phenyl)-1H-imidazo[4,5-f][1,10]phenanthroline) had been synthesized and characterized. Their antimicrobial activities were investigated against Staphylococcus aureus (S. aureus) and four complexes showed obvious antibacterial effect, especially the minimum inhibition concentration (MIC) value of Ru(II)-3 was only 4 μg/mL. In addition, Ru(II)-3 was able to kill bacteria quickly and inhibit the formation of biofilm. Meanwhile, the cooperative effect between Ru(II)-3 and general antibiotics were tested and the results showed that Ru(II)-3 could enhance the susceptibility of S. aureus to different types of antibiotics. Most importantly, Ru(II)-3 hardly showed cytotoxicity to mammalian erythrocytes both in homelysis experiment and G. mellonella model. After being injected with high doses of the Ru(II)-3in vivo, the G. mellonella worms still exhibited high survival rates. Finally, a mouse skin infection model and G. mellonella infection model was built to determine the antibacterial activity of Ru(II)-3in vivo. The antibacterial mechanism of Ru(II)-3 was probably related to the membrane-disruption. Taken together, ruthenium polypyridine complexes with benzyloxyl groups had the potential to develop an attractive and untraditional antibacterial agent with new mode of action.

Manganese(I) Complex with Monodentate Arylisocyanide Ligands Shows Photodissociation Instead of Luminescence.

Recently reported manganese(I) complexes with chelating arylisocyanide ligands exhibit luminescent metal-to-ligand charge-transfer (MLCT) excited states, similar to ruthenium(II) polypyridine complexes with the same d6 valence electron configuration used for many different applications in photophysics and photochemistry. However, chelating arylisocyanide ligands require substantial synthetic effort, and therefore it seemed attractive to explore the possibility of using more readily accessible monodentate arylisocyanides instead. Here, we synthesized the new Mn(I) complex [Mn(CNdippPhOMe2)6]PF6 with the known ligand CNdippPhOMe2 = 4-(3,5-dimethoxyphenyl)-2,6-diisopropylphenylisocyanide. This complex was investigated by NMR spectroscopy, single-crystal structure analysis, high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) measurements, IR spectroscopy supported by density functional theory (DFT) calculations, cyclic voltammetry, and time-resolved as well as steady-state UV–vis absorption spectroscopy. The key finding is that the new Mn(I) complex is nonluminescent and instead undergoes arylisocyanide ligand loss during continuous visible laser irradiation into ligand-centered and charge-transfer absorption bands, presumably owed to the population of dissociative d–d excited states. Thus, it seems that chelating bi- or tridentate binding motifs are essential for obtaining emissive MLCT excited states in manganese(I) arylisocyanides. Our work contributes to understanding the basic properties of photoactive first-row transition metal complexes and could help advance the search for alternatives to precious metal-based luminophores, photocatalysts, and sensors.

Cover Feature: Electrocatalytic CO2 Reduction by Molecular Ruthenium Complexes with Polypyridyl Ligands (Chem. Asian J. 14/2022)

A molecular catalyst toward the CO2 reduction reaction (CO2RR) was searched for in the ‘curious garden’ of polypyridine ruthenium complexes. Two series of ruthenium complexes (eight examples) with various polypyridyl ligands were prepared and assessed for electrocatalytic CO2RR. In wet acetonitrile medium, the complexes bearing a 2,2′:6′,2′′:6′′,2′′′-quaterpyridine ligand scaffold effectively catalyze the CO2 to CO conversion. A maximum turnover frequency of 1084.1 s−1 and a Faradaic efficiency of 66% were achieved under the optimized electrocatalytic conditions. More information can be found in the Research Article by Lianpeng Tong et al.